John E. Timberlake

Valeritas, Inc. engages in the development and commercialization of drug delivery solutions for the treatment of diabetes. Its product, V-Go wearable insulin delivery device, which enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery by using one type of insulin at a continuous preset basal rate over a 24-hour period and provides on-demand bolus dosing for meals and snacks. The company was founded on August 2, 2006 and is headquartered in Bridgewater, NJ.

Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ.

Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY.

Valeritas Holdings, Inc. develops and commercializes insulin delivery devices. The company was founded by Leisa Swanson and Robert R. Gonnelli on August 2, 2006 and is headquartered in Bridgewater, NJ.

Berkshire Biomedical LLC is a medical device company that is pioneering the use of biometric technologies to provide precise and accurate personalized medication delivery to only the authenticated intended user. The private company is based in Dallas, TX. The company's lead product under development is the computerized oral prescription administration system (COPA), a hand-held, automated, personalized oral liquid dispensing system designed to deliver controlled and non-controlled liquid oral medications to only the authenticated intended user upon confirmation of dual biometric identification. The company was founded in 2016 by Thomas M. Rouse, Susan Owen. John E. Timberlake has been the CEO of the company since 2021.

Part of Tandem Diabetes Care, Inc., AMF Medical SA is a Swiss medtech company that was founded in 2014. The company is based in St-Sulpice, Switzerland. The company is developing a novel technology called Sigi™, a next-generation interoperable, semi-reusable, and rechargeable patch pump that uses standard pre-filled insulin cartridges. Sigi™ is designed to make life easier for people with diabetes and received breakthrough device designation by the Food and Drug Administration in November 2021. The company is led by co-CEOs Mr. Pim van Wesel and Mr. Antoine Barraud, PhD, who is also a co-founder. AMF Medical was acquired by Tandem Diabetes Care, Inc. on January 19, 2023, for $205.05 million.